Recap: Medpace Hldgs Q3 Earnings

Shares of Medpace Hldgs MEDP moved lower by 1% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share increased 53.52% year over year to $1.09, which beat the estimate of $1.07.

Revenue of $230,373,000 rose by 6.54% year over year, which beat the estimate of $223,560,000.

Outlook

Medpace Hldgs hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Technicals

52-week high: $144.49

Company's 52-week low was at $58.72

Price action over last quarter: down 4.52%

Company Description

Medpace Holdings Inc is a clinical contract research organization. It is engaged in scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It operates in North America, Europe, Africa, Middle East, Asia-Pacific and Latin America.